This Article Full Text Full Text (PDF) All Versions of this Article: 92/3/932    most recent Author Manuscript (PDF) Submit a related Letter to the Editor View responses Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ali, O. Articles by Cohen, P. Search for Related Content PubMed PubMed Citation Articles by Ali, O. Articles by Cohen, P. Related Collections Pediatric Endocrinology Calcium and Bone Metabolism

Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A Preliminary Pilot Study

David Geffen School of Medicine at University of California, Los Angeles (E.F., M.G., D.P., W.O., P.C.), Los Angeles, California 90095; Southern California Permanente Medical Group (M.S.), Los Angeles, California 90034; and Medical College of Wisconsin (O.A.), Milwaukee, Wisconsin 53226

Address all correspondence and requests for reprints to: Pinchas Cohen, Division of Pediatric Endocrinology, Mattel Children’s Hospital at UCLA, MDCC 22-315, 10833 Le Conte Avenue, Los Angeles, California 90095. E-mail: Hassy{at}mednet.ucla.edu.

Context: Cerebral palsy is associated with osteopenia, increased fracture risk, short stature, and decreased muscle mass, whereas GH therapy is associated with increased bone mineral density (BMD) and linear growth and improvement in body composition.

Objective: We conducted a pilot study to evaluate the effect of 18 months of GH therapy on spinal BMD, linear growth, biochemical markers, and functional measures in children with cerebral palsy.

Design and Setting: The study was a randomized control trial, conducted from 2002–2005 at the University of California, Los Angeles, Orthopedic Hospital’s Center for Cerebral Palsy.

Patients: Patients included 12 males with cerebral palsy, ages 4.5–15.4 yr.

Intervention: We compared 18 months of GH (50 µg daily) vs. no treatment.

Primary Outcome Measures: Spinal BMD (dual-energy x-ray absorptiometry scan), height, growth factors, and bone markers were assessed.

Results: Ten subjects (five in each group) completed the study. Pre- and post-average height z-scores were –1.47 ± 0.23 and 0.8 ± 0.2 (GH-treated group) vs. –1.35 ± 1.26 and –1.36 ± 1.27 (control group) ( SD score, 0.67 vs. –0.01; P = 0.01). Average change in spinal BMD z-score ( SD score corrected for height) was 1.169 ± 0.614 vs. 0.24 ± 0.25 in the treated and control groups, respectively (P = 0.03). Osteocalcin, IGF-I, and IGF-binding protein 3 levels increased during GH therapy. There was no change in quality of life scores as measured by the Pediatric Orthopedic Disability Inventory.

Conclusions: This small pilot study suggests that 18 months of GH therapy is associated with statistically significant improvement in spinal BMD and linear growth.

eLetters: